Equifax Inc. EFX
Verdict: Sell. Fair value $178 against a price of $221 on 6 Jan 2026, 19% below the price.
In plain words
The case for: Wide competitive moat provides durability. Market leadership enables pricing power. Industry tailwinds with growing market.
The case against: Net Income has fluctuated between $0.55B and $0.74B over the past four years, while revenue has....
Main risks
- Negative Incremental Return on Capital (ROIIC ~ -13.5%), suggesting capital deployed over the last 3 years has destroyed value as proxy EBIT has declined.
- Declining Profitability: Net income has fallen from $0.74B in 2021 to $0.60B in 2024 despite a 15% increase in revenue over the same period, indicating significant margin compression.
- Elevated Leverage: Debt-to-Equity ratio is over 1.0 and a proxy for Net Debt to EBITDA is approximately 3.4x, which is in a high-risk zone and could constrain financial flexibility.
- Valuation prices in optimistic scenario (limited margin for error)
- Overhang: The stock has seen a 20% one-year share price pullback, potentially due to broader economi...
- Market volatility